Global CAR-T Cell Therapy for Pediatric Cancers Market - 2024-2031

Overview

Global CAR-T Cell Therapy for Pediatric Cancers Market reached US$ 1.8 billion in 2023 and is expected to reach US$ 11.5 billion by 2031, growing at a CAGR of 27.3% during the forecast period 2024-2031.

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells to fight cancer by changing them genetically engineered in a laboratory.

CAR-T cell therapy is an incredibly promising emerging treatment for cancer patients and is increasingly being preferred over chemotherapy, surgery, and radiation. They can detect and fight cancer cells. This therapy is increasingly used to treat pediatric patients with B-cell acute lymphoblastic leukemia and in certain types of lymphoma.

Market Dynamics: Drivers & Restraints

Rising research and developmental activities in pediatric cancer treatment

Increasing research and development is generating next-generation CAR-T treatments, such as those that use innovative engineering methods and target several antigens. In concern with a variety of pediatric cancers, the major developments increase therapy options and improve the effectiveness of CAR-T therapies.

For instance, on May 28, 2022, Novartis the US Food and Drug Administration (FDA) granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. Kymriah is now FDA-approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings.

Additionally, in April 2023, Autolus Therapeutics plc announced a data update from the AUTO1/22 study (CARPALL) in Pediatric B-cell Acute Lymphoblastic Leukemia in an oral presentation at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in 2023. Thus, innovative approaches could help in driving the overall market growth.

High treatment costs of CAR-T cell therapy

Many patients cannot afford CAR-T cell therapy due to its expensive cost, which frequently exceeds several hundred thousand dollars per patient. This restricts pediatric patients who require potentially life-saving treatments from having access to them. For instance, Kymriah's list price is $475,000, not accounting for costs related to the delivery of care, inpatient hospitalization, toxicity management, or follow-up.

Segment Analysis

The global CAR-T cell therapy for pediatric cancers market is segmented based on cancer type, end-user, and region.

Acute Lymphoblastic Leukemia segment is expected to dominate the market share

Acute Lymphoblastic Leukemia (ALL) accounted for the major portion of the CAR-T cell therapy market. This is due to the increasing incidence of cancers. CAR T-cell therapy is approved for the treatment of children and adolescents with fairly advanced B-cell acute lymphoblastic leukemia (ALL). Because of the increasing incidence rate, more patients are benefiting from CAR-T therapy, which is boosting the segment growth.

For instance, according to the American Cancer Society in 2024, leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. About 3 out of 4 leukemias among children and teens are acute lymphocytic leukemia (ALL).

High rates of total recovery have been achieved with CAR-T treatments, especially those that target CD19 such as Kymriah, which have demonstrated remarkable success in treating relapsed or refractory B-cell ALL. Because of this achievement, CAR-T is now the suggested method of treatment for this group of patients. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the CAR-T cell therapy for pediatric cancers market share

North America accounts for the largest share of the global CAR-T Cell Therapy market. The region is expected to hold a significant portion of the market share owing to the rising incidence of cancer in the region, the increasing awareness among the public regarding treatment options, and the increasing research and development of new CAR-T cell therapies for children.

There is an increased risk of pediatric cancers in the US. Several sources are estimating a rapid increase in cancers among children. For instance, according to the About 9,620 children in the United States under the age of 15 will be diagnosed with cancer in 2024. After accidents, cancer is the second leading cause of death in children ages 1 to 14. About 1,040 children under the age of 15 are expected to die from cancer in 2024.

With the increasing number of cancers, there will be an increasing demand and need for the therapies. This is expected to drive the region's market growth and is expected to hold the major position in the market share.

Market Segmentation

By Cancer Type

• Acute Lymphoblastic Leukemia (ALL)
• Multiple Myeloma
• Non-Hodgkin Lymphoma
• Others

By End-User

• Hospitals
• Cancer Centers
• Research Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Novartis AG, Seattle Children's Hospital, Autolus Therapeutics, and Baylor College of Medicine among others.

Why Purchase the Report?

• To visualize the global CAR-T cell therapy for pediatric cancers market segmentation based on cancer type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of CAR-T cell therapy for pediatric cancers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global CAR-T cell therapy for pediatric cancers market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies